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Chondrocyte hypertrophy is essential for endo-
chondral bone development. Unexpectedly, we
discovered that MEF2C, a transcription factor
that regulates muscle and cardiovascular de-
velopment, controls bone development by acti-
vating the gene program for chondrocyte
hypertrophy. Genetic deletion of Mef2c or ex-
pression of a dominant-negative MEF2C mu-
tant in endochondral cartilage impairs hypertro-
phy, cartilage angiogenesis, ossification, and
longitudinal bone growth in mice. Conversely,
a superactivating form ofMEF2C causes preco-
cious chondrocyte hypertrophy, ossification of
growth plates, and dwarfism. Endochondral
bone formation is exquisitely sensitive to the
balance between MEF2C and the corepressor
histone deacetylase 4 (HDAC4), such that
bone deficiency of Mef2c mutant mice can be
rescued by an Hdac4mutation, and ectopic os-
sification in Hdac4 null mice can be diminished
by a heterozygousMef2cmutation. These find-
ings reveal unexpected commonalities in the
mechanisms governing muscle, cardiovascu-
lar, and bone development with respect to their
regulation by MEF2 and class II HDACs.
INTRODUCTION
The vertebrate skeleton is comprised of endochondral
and membranous bones, which form through different
mechanisms (Olsen et al., 2000; Nakashima and de Crom-
brugghe, 2003; Kronenberg, 2003; Karsenty, 2003). Endo-
chondral bones, which account for all the bones of the
body, with the exception of the craniofacial bones and
the clavicle, develop from a cartilaginous template. In con-
trast, membranous bones are derived from mesenchymal
cells, which differentiate directly into osteoblasts withoutDevelopa cartilaginous intermediate. There are also permanent
cartilaginous structures throughout the body, such as
those located in ears, nose, throat, joints, and segments
of the ribs. Why the cartilage in these regions fails to un-
dergo ossification is unknown.
Endochondral bone formation begins with the aggrega-
tion of mesenchymal cells and their differentiation into
chondrocytes. Chondrocyte hypertrophy, which initiates
in the center of cartilaginous skeletal elements, drives lon-
gitudinal bone growth. This process is coupled to exit from
the cell cycle and is marked by the expression of specific
extracellular matrix molecules, such as a1(X) collagen
(Col10a1). Chondrocyte hypertrophy is followed by apo-
ptosis; invasion of blood vessels, osteoclasts, and other
mesenchymal cells from the perichondrium; and produc-
tion of the mature bone matrix. The ultimate sizes and
structures of endochondral bones depend on the coordi-
nated regulation of chondrocyte proliferation, maturation,
and hypertrophy in response to multiple extracellular sig-
nals. Indian hedgehog (Ihh) and Parathyroid hormone-
related peptide (PTHrP) play critical roles in coordinating
these processes (Karaplis et al., 1994; Lanske et al.,
1996; Weir et al., 1996; Vortkamp et al., 1996; St-Jacques
et al., 1999). Ihh produced by prehypertrophic chondro-
cytes induces the expression of PTHrP, which regulates
the rate at which chondrocytes exit the cell cycle and un-
dergo hypertrophy. Ihh also stimulates chondrocyte prolif-
eration and controls the differentiation of mesenchymal
cells into osteoblasts within the bone collar. VEGF ex-
pressed by hypertrophic chondrocytes is required for
chondrocyte survival and cartilage angiogenesis (Zelzer
et al., 2004).
Several transcription factors that control the patterning
and maturation of the endochondral skeleton have been
identified (reviewed in Karsenty, 2003; Zelzer and Olsen,
2003; Lefebvre and Smits, 2005). Runx2 and Runx3,
members of the Runt family of transcription factors, are
necessary for chondrocyte hypertrophy and osteoblast
differentiation (Komori et al., 1997; Yoshida et al., 2004).
Chondrocyte hypertrophy is arrested during the late
stages of maturation in Runx2 null mice, and it is com-
pletely blocked in mice lacking Runx2 and Runx3,mental Cell 12, 377–389, March 2007 ª2007 Elsevier Inc. 377
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cyte differentiation. The zinc finger transcription factor os-
terix acts downstream of Runx2 and is required for osteo-
blast differentiation and bone formation (Nakashima et al.,
2002, Nishio et al., 2006). Mice lacking the HMG box tran-
scription factor Sox9 display hypoplasia of endochondral
skeletal elements, resembling the defects associated with
campomelic dysplasia in humans (Bi et al., 2001). Sox5
and Sox6 have also been implicated in chondrocyte
differentiation (Smits et al., 2001).
Recently, we reported that histone deacetylase 4
(HDAC4) acts as a negative regulator of chondrocyte hy-
pertrophy (Vega et al., 2004). Hdac4 null mice die during
the perinatal period due to premature and ectopic chon-
drocyte hypertrophy and ossification of endochondral
cartilage. HDAC4 and other class II HDACs establish core-
pressor complexes with DNA-binding transcription fac-
tors (Miska et al., 1999; Lu et al., 2000; reviewed in Verdin
et al., 2003), including myocyte enhancer factor-2 (MEF2),
a MADS (MCM1, Agamous, Deficiens, serum response
factor) box factor implicated in muscle and cardiovascular
development (reviewed in McKinsey et al., 2002; Black
and Olson, 1998). There are four mammalianMef2 genes,
Mef2a,Mef2b,Mef2c, andMef2d, which are expressed in
complex and overlapping patterns in embryonic and adult
tissues (Edmondson et al., 1994). Mef2c null mice die by
embryonic day 9.5 (E9.5) from abnormal cardiovascular
development (Lin et al., 1997, 1998), whereas Mef2a null
mice die perinatally from a spectrum of heart defects
(Naya et al., 2002).
Here, we demonstrate the previously undescribed ex-
pression of Mef2 genes in developing chondrocytes, and
we show that MEF2C plays an unexpected role in endo-
chondral bone development. Conditional deletion of
Mef2c or expression of a dominant-negative mutant of
MEF2C in developing cartilage impairs chondrocyte hy-
pertrophy and subsequent growth plate vascularization
and endochondral ossification. Conversely, a superacti-
vating form of MEF2C promotes precocious chondrocyte
hypertrophy and ossification of endochondral bones. De-
letion of Hdac4 restores normal bone formation in hetero-
zygousMef2cmutant mice, and deletion of a singleMef2c
allele prevents excessive and ectopic bone formation
in Hdac4 mutant mice. We conclude that MEF2C acts
as an essential, early regulator of bone development
by orchestrating transcriptional and cell-cell signaling
events involved in chondrocyte hypertrophy. These
findings highlight the partnership of MEF2 and class II
HDACs as a nodal point in the control of the seemingly
unrelated processes of muscle, cardiovascular, and bone
development.
RESULTS
Expression of Mef2 Genes in the Developing
Skeleton
While analyzing the expression of Mef2 genes dur-
ing mouse embryogenesis, we found that Mef2c was
expressed in the mesenchymal primordium of the378 Developmental Cell 12, 377–389, March 2007 ª2007 Elsevendochondral cartilage at E12.5 (Figure 1Ac) and that
bothMef2c andMef2dwere expressed in prehypertrophic
and hypertrophic chondrocytes, as well as in the spon-
giosa of developing endochondral bones at later stages
of bone development (Figure 1A). It is noteworthy that
the level of Mef2c and Mef2d expression in hypertrophic
chondrocytes was comparable to that in surrounding skel-
etal muscle (Figure 1A).Mef2a transcripts were detectable
at lower levels, andMef2b expression was not detectable
in the developing skeleton (Figure 1A).
A Heterozygous Mef2c Mutation Impairs Bone
Development
Mice homozygous for a Mef2c null mutation die at E9.5
from defects in cardiovascular development (Lin et al.,
1997), precluding an analysis of potential functions of
Mef2c at later developmental stages. In light of the ex-
pression of Mef2c in the developing endochondral skele-
ton, we analyzed Mef2c+/ mice for possible skeletal ab-
normalities and noticed a lack of ossification within the
sternum at postnatal day (P) 1 (compare Figure 1Ba and
Figure 1Bb). Typically, the sternum contains trabeculated
bone within each sternebra, with growth plates at both
ends. In contrast to wild-typemice in which the sternebrae
and xiphoid process are ossified by P1, these structures
remained cartilaginous in mutant mice (Figure 1B). Histo-
logical analysis and von Kossa staining, which detects cal-
cium deposits within the mineralized cartilaginous matrix,
showed only residual hypertrophic chondrocytes and
almost a complete absence of trabeculated bone in the
sternum of Mef2c+/ mutants at P1. We did not detect
abnormalities in other endochondral skeletal elements of
Mef2c+/ mutants, indicating that the sternum is most
sensitive to levels of Mef2c expression at this stage.
Mice homozygous for a Mef2d null allele are viable and
show no skeletal abnormalities (unpublished data). In light
of the expression ofMef2d in the developing skeleton, we
generated Mef2c+/; Mef2d+/ double heterozygous mu-
tant mice to test for potential functional redundancy of
these genes in skeletal development. Indeed, Mef2c+/;
Mef2d+/ mutants displayed a deficiency in ossification
of the sternummore severe than that ofMef2c+/mutants
(Figure 1B). Histological analysis revealed almost no hy-
pertrophic chondrocytes in the sternum of Mef2c+/;
Mef2d+/mice. In situ hybridization showed a1(II) collagen
(Col2a1) expression, a marker of proliferating chondro-
cytes, throughout the sternum of Mef2c+/; Mef2d+/
mice at P1, whereas Col2a1 expression was excluded
from the hypertrophic and mineralized regions of the
wild-type sternum (Figure 1C). In contrast, Col10a1,
Col1a1, and bone sialoprotein, which are markers of hy-
pertrophic chondrocytes, trabeculated bone, and differ-
entiated osteoblasts, respectively, were not expressed
in the mutants (Figure 1C). Mef2c+/; Mef2d+/ mutant
mice died within a day after birth; thus, we were unable
to analyze them for possible skeletal abnormalities later
in postnatal development. These findings suggested that
MEF2C played an essential role in bone development,
and that MEF2D augmented this function of MEF2C.ier Inc.
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Control of Bone Development by MEF2CFigure 1. Mef2 Expression in Developing
Endochondral Bones and Skeletal De-
fects in HeterozygousMef2Mutant Mice
(A) Detection of Mef2 transcripts by in situ
hybridization to sections of the developing
radius at (Aa–Ad) E12.5, (Ag–Aj) E14.5, and
(Am–Ap) E16.5. Expression of Mef2c is initially
observed in the cartilage primordium at E12.5.
Mef2c and Mef2d are expressed in prehyper-
trophic and hypertrophic chondrocytes at later
stages. Expression of (Ae, Ak, and Aq) Col2a1
and (Af, Al, and Ar) Col10a1 are also described
to show chondrocyte differentiation.
(B) (Ba–Bc) Anterior views of the sternum and
ribs of mice stained for bone (red) and cartilage
(blue) at P1. The xiphoid process (x) is indi-
cated. Note the reduction in ossification of
the sternum in (Bb) and the complete absence
of ossification in (Bc). Hematoxylin and eosin
(H&E)-stained sections are shown in (Bd)–(Bf),
and a high-magnification view of the sterne-
brae is shown below in (Bg)–(Bi). Note the
absence of hypertrophic chondrocytes and
trabeculation in the mutants. (Bj–Bl) von
Kossa-stained sections are shown at the
bottom.
(C) Detection of markers of bone development
by in situ hybridization to sections of sternum
from wild-type and Mef2c+/; Mef2d+/ mice
at P1.Generation of a Conditional Mef2c Allele
To further investigate the potential involvement ofMef2c in
bone development, we generated a conditionalMef2c null
allele, called Mef2cloxP, that contained loxP sites in the
introns flanking the second coding exon. This exon
encodes the MADS- and MEF2-specific domains, which,
in turn, mediate DNA binding, dimerization, and cofactor
interactions. Deletion of the genomic region between the
loxP sites inactivates the gene (Figure S1, see the Supple-
mental Data available with this article online). A similar
genomic region was deleted in our original Mef2cKO null
allele (Lin et al., 1997). Mice homozygous for theMef2cloxP
allele or trans-heterozygous for this allele and theMef2cKODevelopallele showed no apparent abnormalities, indicating that
the Mef2cloxP allele functioned normally.
Conditional Deletion of Mef2c Disrupts Bone
Development
We used two mouse lines that express Cre recombinase
in different skeletal elements and their precursors to con-
ditionally deleteMef2c in vivo. We deletedMef2c from the
early precursors of all cell types of the developing bone by
using the Twist2-Cre knockin (Yu et al., 2003), or we de-
leted the gene specifically in the cartilaginous template
of endochondral bones by using Col2-Cre (Long et al.,
2001). The expression of Mef2c was effectively reducedmental Cell 12, 377–389, March 2007 ª2007 Elsevier Inc. 379
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Control of Bone Development by MEF2CFigure 2. Failure in Endochondral Ossification after Conditional Deletion of Mef2c by Using Twist2-Cre
(A) Alizarin red and Alcian blue staining of P1 wild-type and Mef2cloxP/KO; Twist2-Cre whole skeletons in (Aa and Ac) lateral and (Ab and Ad) dorsal
views. Arrows in (Ab) and (Ad) indicate the supraoccipital bone (so) and vertebral bodies (v), which fail to ossify in Mef2cloxP/KO; Twist2-Cre mice.
(B) Alizarin red and Alcian blue staining of P1 wild-type andMef2cloxP/KO; Twist2-Cre bones of the sternum, forelimb, and hindlimb, as indicated. Many
phalangeal bones of the forelimb fail to ossify in the mutant (arrow in [Bf]). Arrows indicate the tibia and fibula in (Bh), in which ossification is severely
disrupted. Bones of Mef2cloxP/KO; Twist2-Cre mice contain excessive cartilage, and bone collars are disorganized.
(C) Histologic sections of P1 wild-type andMef2cloxP/KO; Twist2-Cre sternum and radius stained with H&E or by von Kossa’s method. The sternum of
Mef2cloxP/KO; Twist2-Cremice does not contain hypertrophic chondrocytes, while the radius is filled with cartilage that has undergone limited hyper-
trophic differentiation. (Cb), (Ce), (Ch), (Ci), (Cl), and (Cm) show enlargements of the boxed regions in (Ca), (Cd), (Cg), and (Ck), respectively.as a result of Cre expression (Figure S1D and data not
shown).
Mef2cloxP/KO; Twist2-Cre mice were readily identifiable
at birth by their shortened limbs (Figures 2A and 2B). A
fraction of these conditionalMef2cmutants also displayed
difficulty breathing, evidenced by gasping and accumula-
tion of air in their intestines, and none survived beyond the380 Developmental Cell 12, 377–389, March 2007 ª2007 Elsefirst week of postnatal life. Analysis of the skeletons of
Mef2cloxP/KO; Twist2-Cre mice revealed severe defects
in ossification of nearly all endochondral bones (Figures
2A and 2B). This phenotype was especially pronounced
in the sternum (compare Figure 2Ba and Figure 2Be). Sim-
ilarly, the vertebral bodies failed to ossify, as did the supra-
occipital bone, which defines the dorsal margin of thevier Inc.
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Control of Bone Development by MEF2Cforamen magnum (arrows in Figure 2Ad). There was also
obvious foreshortening of the ossified regions of the
bones of the fore and hindlimbs and lack of ossification
in many phalangeal bones of the digits (Figure 2B). Trun-
cation of the tibia and fibula was particularly severe (com-
pare Figure 2Bd and Figure 2Bh). Ossification of the bone
collar also appeared disorganized in these mutant mice
(Figure 2B).
Histological sections of the sternum and radius revealed
that the defects in endochondral ossification in the mu-
tants resulted from a failure in chondrocyte hypertrophy
(Figure 2C). von Kossa staining showed that the sternum
and radius of Mef2cloxP/KO; Twist2-Cre mice were com-
pletely devoid of trabeculated bone (Figure 2C). However,
weak von Kossa staining was seen at the midpoint of the
mutant radius and in the surrounding bone collar of the
mutants, indicative of a few chondrocytes in the late
stages of hypertrophic differentiation. Bone collar forma-
tion is secondary to chondrocyte hypertrophy; therefore,
it did not occur in the mutant sternum, where chondrocyte
hypertrophy failed to take place (Figure 2C). In the mutant
radius, a disorganized bone collar was present only near
the midpoint of the bone, where residual hypertrophic
chondrocytes were present (Figure 2C).
Deletion of Mef2c with Col2-Cre
Todistinguishwhether the skeletal defects inMef2cloxP/KO;
Twist2-Cre mice reflected a role for MEF2C in chondro-
cytes or osteoblasts, we specifically deleted Mef2c in
proliferating chondrocytes by using a Cre transgene
controlled by the Col2a1 promoter, called Col2-Cre. The
resulting mutants were identifiable at birth by shortened
limbs,anabsenceofossificationof thesternum(Figure3A),
and a failure in chondrocyte hypertrophy (Figure 3B), sim-
ilar to the defects seen inMef2cloxP/KO; Twist2-Cre mice.
Mef2cloxP/KO; Col2-Cre mice survived to adulthood and
remained distinguishable from wild-type littermates by
their waddling gait due to their shortened limbs. Bone
and cartilage staining of skeletons of 3-month-old mutant
mice highlighted the truncation of all long bones of the
limbs (Figure 3C). The structures of the distal ribs, radii,
and sternabrae were also distorted by disorganized carti-
laginous remnants of the growth plate and aberrant ossifi-
cation (Figure 3D), demonstrating the requirement for
MEF2C in timely chondrocyte maturation.
Chondrocyte Deletion of Mef2c and Mef2d
Our earlier finding that deletion of one Mef2d allele exac-
erbated the bone defects in Mef2c+/ mice suggested
that these two Mef2 genes acted cooperatively to control
chondrocyte hypertrophy. Because Mef2c+/; Mef2d+/
mice were not viable, it was necessary to generate a con-
ditional Mef2d allele in order to examine possible redun-
dant functions of MEF2C and MEF2D in the developing
skeleton. As shown in Figures 3Ai–3Al, homozygous
deletion of both genes by usingCol2-Cre resulted in a skel-
etal phenotype more severe than that of Mef2cloxP/KO;
Col2-Cre mice, in which nearly all mineralized endochon-
dral skeletal elements were missing.DeveloRequirement of MEF2C for Activation of the Gene
Program for Chondrocyte Hypertrophy and
Vascularization
To precisely define the molecular defects resulting from
the absence of MEF2C expression in the endochondral
skeleton, we analyzed numerous markers of skeletal
development in the radius (Figure 4) and sternum
(Figure S2) of Mef2cloxP/KO; Twist2-Cre mice at E14.5
and P1. At both stages, Col2a1, a marker of proliferating
chondrocytes, failed to be downregulated in mutant chon-
drocytes (Figures 4A and 4B). Col10a1, which is ex-
pressed in a specific zone of hypertrophic chondrocytes
of normal bones, was not expressed in the radius of
Mef2cloxP/KO; Twist2-Cre mutant mice at E14.5, and at
P1 we detected only diffuse Col10a1 expression in a few
residual hypertrophic chondrocytes scattered throughout
the length of the radius (Figures 4A and 4B), suggesting
a severe developmental delay in the timing and extent of
chondrocyte hypertrophy. There was no detectable ex-
pression of Col1a1, a marker of ossification, in the radius
or sternum of the mutants at these stages. Similarly, os-
teocalcin, a marker of osteoblasts, was not detected
within the endochondral skeleton of mutant mice, consis-
tent with the failure in endochondral ossification.
Runx2, which is normally expressed at high levels in
prehypertrophic and hypertrophic chondrocytes and os-
teoblasts, failed to be upregulated in endochondral skele-
tal elements of Mef2cloxP/KO; Twist2-Cre mutant mice at
P1 (Figure 4B), although Runx2 expression was detected
in the bone collar of the mutant. Ihh is expressed in prehy-
pertrophic chondrocytes and induces PTHrP expression
in adjacent chondrocytes, resulting in a delay in chondro-
cyte hypertrophy (Vortkamp et al., 1996; St-Jacques et al.,
1999). In mutant mice, Ihh was expressed diffusely in pre-
hypertrophic chondrocytes, but it did not show the nor-
mally localized expression to the prehypertrophic zone
(Figure 4B). The diffuse expression of Ihh likely reflects,
at least in part, the failure in chondrocyte hypertrophy,
which typically results in the organization of chondrocytes
into a distinct prehypertrophic cell layer. The PTHrP re-
ceptor (Ppr) was expressed in prehypertrophic chondro-
cytes of wild-type and mutant skeletal elements. VEGF
is normally upregulated in hypertrophic chondrocytes of
the growth plate, where it stimulates cartilage vasculariza-
tion (Zelzer et al., 2004). VEGF failed to be upregulated in
endochondral cartilage of Mef2cloxP/KO; Twist2-Cre mice,
and there was a complete absence of vascularization, as
assayed by staining for endomucin (Figure 4B). In con-
trast, the perichondrium and surrounding tissue were nor-
mally vascularized in the mutant. Thus, MEF2C is required
specifically in endochondral cartilage for VEGF expres-
sion and blood vessel invasion.
Blockade to Chondrocyte Hypertrophy
by Dominant-Negative MEF2C
The residual chondrocyte hypertrophy and ossification
seen in Mef2c; Mef2d mutant mice could reflect partial
functional redundancy with Mef2a or incomplete deletion
of these conditional alleles. As an independent means ofpmental Cell 12, 377–389, March 2007 ª2007 Elsevier Inc. 381
Developmental Cell
Control of Bone Development by MEF2CFigure 3. Failure in Endochondral Ossification after Conditional Deletion of Mef2c and Mef2d by Using Col2-Cre
(A) Alizarin red and Alcian blue staining of P1 wild-type, Mef2cloxP/KO; Col2-Cre, and Mef2cloxP/loxP; Mef2dloxP/loxP; Col2-Cre bones of the sternum,
forelimb, and hindlimb, as indicated. Bones of theMef2cloxP/KO; Col2-Cremice contain large amounts of cartilage, and bone collars are disorganized.
Many phalangeal bones of the paw fail to ossify in the mutant (arrow in [Af]). InMef2c; Mef2d double mutants, there is almost a complete absence of
bone formation.
(B) Histologic sections of P1 wild-type,Mef2cloxP/KO; Col2-Cre andMef2cloxP/loxP; Mef2dloxP/loxP; Col2-Cre radius stained with H&E or by von Kossa’s
method. The radius of the mutant is filled with cartilage that has undergone only limited hypertrophic differentiation and no mineralization. (Bb), (Be),
(Bf), (Bi), and (Bj) show enlargements of the boxed regions of the adjacent panels (Ba, Bd, and Bh). Note the more severe defects in Mef2c; Mef2d
double mutants than in Mef2c mutants (compare [Bg] and [Bk]).
(C) Alizarin red and Alcian blue staining of 3-month-old wild-type and Mef2cloxP/KO; Col2-Cre bones of the (Ca and Cb) whole skeleton, (Cc and Cd)
sternum, and (Ce and Cf) ribs. The limbs of theMef2cloxP/KO; Col2-Cre skeleton are shortened. Brackets in (Ca) and (Cb) correspond to the length of
thewild-type tibia. The sternum and ribs of theMef2cloxP/KO; Col2-Cre skeleton contain large cartilaginous growth plate remnants that distort the bone
architecture.
(D) Histologic sections of 3-month-oldwild-type andMef2cloxP/KO; Col2-Cre (Da andDb) radius, (Dc andDd) ribs, and (De and Df) sternum stainedwith
H&E. The radius and ribs of theMef2cloxP/KO; Col2-Cre skeleton contain large cartilaginous growth plate remnants, and the sternum is filled with par-
tially ossified cartilage. Brackets indicate the position and length of the remaining growth plate cartilages.382 Developmental Cell 12, 377–389, March 2007 ª2007 Elsevier Inc.
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Control of Bone Development by MEF2CFigure 4. Detection of Markers of Bone Development in Wild-Type and Mef2cloxP/KO; Twist2-Cre Mice
(A and B) Transcripts for the indicated markers of bone development were detected by in situ hybridization to sections of the radius of wild-type (top
row) andMef2cloxP/KO; Twist2-Cre (bottom row)mice at (A) E14.5 and (B) P1. Endomucin expression was detected by immunostaining. Brackets in (Bf)
show the region of prehypertrophic chondrocytes.inactivating the multiple MEF2 factors expressed in devel-
oping endochondral cartilage, we generated transgenic
mice that expressed a fusion protein of the MEF2C
DNA-binding domain and the Engrailed repressor in prolif-
erating chondrocytes under control of the Col2a1 pro-
moter. This MEF2C-Engrailed fusion protein inactivates
all MEF2 proteins by preventing DNA binding and creating
transcriptionally inactive heterodimers with wild-type
MEF2 proteins. Ossification in nearly every region of the
endochondral skeleton was blocked in MEF2C-Engrailed
transgenic mice, while formation of cartilage-independent
membranous bones was unaffected (Figure 5). All endo-
chondral bones of these transgenic mice were also hypo-
plastic, resulting in shortening of the limbs, spine, and pel-
vis and deformation of the rib cage. In the most strongly
affected animals, the endochondral bones at the base of
the skull, the hyoid bone, the bones of the limbs, the ster-
num, and the pelvis remained entirely cartilaginous (Fig-
ures 5A, 5B, and 5D and data not shown). Milder defects
were observed in transgenic mice carrying fewer copies
of the transgene (data not shown). Histologic sections of
the sternum and forelimb demonstrated that chondrocyte
hypertrophy in these transgenic mice was completely
absent (Figure 5C).
Excessive Ossification in Response to MEF2C-VP16
To determine if MEF2 was sufficient to induce chondro-
cyte hypertrophy and bone formation, we generated
transgenic mice that expressed a superactive MEF2C-
VP16 fusion protein under control of the Col2a1 promoter.
In contrast to the MEF2C-Engrailed transgenic mice, ex-
pression of MEF2C-VP16 in endochondral cartilage of
transgenic mice resulted in premature endochondral ossi-
fication at E18.5, with consequent foreshortening of the
limbs (Figure 5). This phenotype of excessive ossification
was especially apparent in the sternum and vertebrae
(Figure 5B). Growth plates separating the sternebrae
were prematurely ossified, resulting in complete ossifica-
tion along the length of the sternum (Figure 5Bh). In con-Developtrast to normal vertebrae at E18.5, which contain a carti-
laginous growth plate surrounding the vertebral body
(Figure 5Ba), the entire vertebra was ossified, due to pre-
mature fusion of the growth plates between the vertebral
body and the lateral vertebral processes (Figure 5Bg).
Growth plate cartilages of the limbs were also inappropri-
ately ossified inMEF2C-VP16 transgenicmice, resulting in
distortion of the forelimb (Figure 5Bi). Inappropriate ossifi-
cation in MEF2C-VP16 transgenic mice was also promi-
nent in the base of the skull, where premature fusion of
the endochondral growth plates resulted in deformation
of the cranial vault (Figures 5Ac and 5Dc). In contrast, for-
mation of cartilage-independent membranous bones was
unaffected. Histologic examination of the sternum and
forearm confirmed that growth plate maturation was ac-
celerated, particularly in the sternum, where nearly all
chondrocytes in the growth plate were consumed by pre-
mature differentiation (Figure 5Cf).
Activation of the Col10a1 Promoter by MEF2C
The bone abnormalities resulting fromMef2c deletion and
MEF2C-Engrailed expression suggested that MEF2 was
required for activation of a hypertrophic gene program in
chondrocytes. Analysis of the promoter region of the
Col10a1 gene, the prototypical marker of chondrocyte hy-
pertrophy (Gebhard et al., 2004), revealed several evolu-
tionarily conserved sequences resembling MEF2-binding
sites (Figure 6A), and gel mobility shift assays confirmed
that MEF2 bound with varying affinities to a subset of
these sites (Figure 6C). Transfection assays also showed
that MEF2 could activate the Col10a1 promoter, and mu-
tation of the MEF2 sites eliminated MEF2 responsiveness
(Figure 6B). As previously reported (Gebhard et al., 2004),
the 50 flanking region of the Col10a1 gene was able to di-
rect the expression of a lacZ reporter in hypertrophic
chondrocytes of developing endochondral bones of trans-
genicmice, in a pattern that recapitulated the endogenous
expression pattern of the Col10a1 gene (Figures 6D and
6E). Mutation of the MEF2 DNA-binding sites in themental Cell 12, 377–389, March 2007 ª2007 Elsevier Inc. 383
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Control of Bone Development by MEF2CFigure 5. Regulation of Bone Development by Dominant-Negative and Activating Forms of MEF2C
(A) Alizarin red and Alcian blue staining of (Aa) wild-type, (Ab) Col2-MEF2C-Engrailed transgenic, and (Ac) Col2-MEF2C-VP16 transgenic E18.5 em-
bryos depicting a dorsal view of whole skeletons. Arrows indicate the supraoccipital bone (so), the first cervical vertebrae (cv), the clavicle (c), the
femur (f), and the pelvis (p).
(B) Alizarin red and Alcian blue staining of (Ba–Bc) wild-type, (Bd–Bf) Col2-MEF2C-Engrailed transgenic, and (Bg–Bi) Col2-MEF2C-VP16 transgenic
E18.5 embryos depicting (Ba, Bd, and Bg) spine, (Bb, Be, and Bh) sternum, and (Bc, Bf, and Bi) forelimb. Elements of the endochondral skeleton
remain cartilaginous in Col2-MEF2C-Engrailed transgenic embryos, and endochondral skeletal elements of Col2-MEF2C-VP16 transgenic embryos
are prematurely ossified (arrows in [Bg] and [Bh]).
(C) Sections of (Ca, Cd, and Cg) wild-type, (Cb, Ce, and Ch) Col2-MEF2C-Engrailed transgenic, and (Cc, Cf, and Ci) Col2-MEF2C-VP16 transgenic
E18.5 embryos stained with H&E depicting the (Ca–Cf) sternum or (Cg–Ci) forelimb of the indicated embryos. The radius (r) and ulna (u) are indicated in
(Cg)–(Ci). (Cd)–(Cf) are enlargements of the boxed regions of (Ca)–(Cc), respectively. Chondrocytes in the sternum and radius of Col2-MEF2C-
Engrailed transgenic embryos fail to initiate hypertrophic differentiation; conversely, in Col2-MEF2C-VP16 transgenic embryos, chondrocyte hyper-
trophic differentiation is accelerated and has consumed nearly all growth plate chondrocytes.
(D) Alizarin red and Alcian blue staining of (Da) wild-type, (Db) Col2-MEF2C-Engrailed transgenic, and (Dc) Col2-MEF2C-VP16 transgenic E18.5 em-
bryos depicting the ventral skull. The endochondral basioccipital (1), basisphenoid (2), and presphenoid (3) bones are indicated. These bones fail to
ossify in Col2-MEF2C-Engrailed transgenic embryos, and they prematurely fuse in Col2-MEF2C-VP16 transgenic embryos (arrow in [Dc]).promoter diminished expression in hypertrophic chondro-
cytes in vivo. These results identify MEF2 as a direct acti-
vator of chondrocyte gene expression and a critical con-
trol point in regulating chondrocyte hypertrophy in vivo.
Genetic Antagonism between Mef2c and Hdac4
The decreased ossification observed in Mef2c mutant
mice contrasts with the precocious and ectopic ossifica-
tion of endochondral cartilage in mice lacking HDAC4,384 Developmental Cell 12, 377–389, March 2007 ª2007 Elseviera MEF2 corepressor (Vega et al., 2004). Thus, we won-
dered whether the repressive effects of HDAC4 on bone
development might be mediated, at least in part, by
MEF2. Consistent with this notion, expression of a
constitutively nuclear HDAC4 blocked activation of the
Col10a1 promoter by MEF2C (Figure 6B).
To test for potential genetic interactions betweenMef2c
and Hdac4 in vivo, we investigated whether deletion of
oneMef2c allele might diminish the excessive and ectopicInc.
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Control of Bone Development by MEF2Cossification of endochondral cartilage seen in Hdac4 null
mice (Vega et al., 2004). Indeed, deletion of oneMef2c al-
lele in Hdac4/mice normalized ossification of the chon-
drocostal cartilage and sternum (Figure 6F). Conversely,
deletion of one copy of the Hdac4 gene in the Mef2c+/
background partially restored ossification of the sternum
and increased ossification in the xiphoid process, and de-
letion of both copies ofHdac4 in the presence of a hetero-
zygous Mef2c allele resulted in a nearly normal pattern
of ossification in the sternum (Figure 6F). Similar rescue of
normal ossification was seen in endochondral bones of
the skull and the hyoid bone (data not shown). These find-
ings demonstrate that ossification of endochondral carti-
lage depends on the balance between transcriptional
activation by MEF2C and repression by HDAC4.
DISCUSSION
The results of this study reveal the following insights into
the molecular basis of bone development and the role of
MEF2C in this process. (1) MEF2C is a necessary early
regulator of chondrocyte hypertrophy and subsequent
growth plate maturation. The extent of chondrocyte hy-
pertrophy and bone formation in vivo directly reflects the
level of MEF2C transcriptional activity in chondrocytes,
as shown by the perturbation of these processes with
even a heterozygous Mef2c mutation. (2) MEF2C is suffi-
cient to induce chondrocyte hypertrophy and bone forma-
tion in vivo, as revealed by the stimulation of these pro-
cesses by MEF2C-VP16 in vivo. (3) MEF2D augments
the prohypertrophic actions of MEF2C in chondrocytes.
(4) MEF2C is a direct regulator of Col10a1 transcription
and is required for appropriate temporal and spatial ex-
pression of the genetic program of chondrocyte develop-
ment, including expression of Runx2 and VEGF in endo-
chondral cartilage. (5) Chondrocyte hypertrophy and
bone formation depend on the balance between the op-
posing actions of MEF2C and HDAC4. We conclude that
MEF2C is a key regulator of chondrocyte development
that orchestrates multiple steps in the transcriptional
program for bone formation, as schematized in Figure 7.
Control of Chondrocyte Hypertrophy by MEF2C
Growth of endochondral bone requires a tightly regulated
sequence of developmental steps in which proliferating
chondrocytes in the growth plate exit the cell cycle and
undergo hypertrophy. Hypertrophic chondrocytes secrete
a calcified extracellular matrix and undergo apoptosis.
Osteoblasts then invade the cartilaginous skeleton and
deposit bone on the mineralized cartilaginous spicules of
the primary spongiosa. Lengthwise bone growth is driven
by the dynamics of chondrocyte proliferation, differentia-
tion, and hypertrophy within the growth plates (reviewed
in Olsen et al., 2000). Mef2c is expressed in prehypertro-
phic and hypertrophic chondrocytes, and its specific
deletion from this cell population impairs hypertrophy,
with consequent short-limb dwarfism. Deletion of Mef2d
exacerbates the bone defects associated with a Mef2c
mutation, and expression of a dominant-negativeMEF2C-DevelopmEngrailed fusion protein in endochondral cartilage pre-
vents hypertrophy and ossification. The importance of
MEF2C as a regulator of chondrocyte hypertrophy and
bone formation is underscored by the ability of the super-
activating MEF2C-VP16 fusion protein to promote preco-
cious ossification of endochondral bones and dwarfism
due to premature growth plate fusion.
Runx2mutant mice also display defects in chondrocyte
hypertrophy and ossification, but the phenotypes of
Runx2 and Mef2c mutant mice differ in several important
respects that highlight the distinct functions of these
genes. For example, only a relatively small subset of chon-
drocytes displays defects in hypertrophy in Runx2mutant
mice, whereas osteoblasts are missing in these mice, re-
sulting in an absence of membranous and endochondral
ossification (Komori et al., 1997). Deletion of Mef2c from
multiple mesodermal lineages, including chondrocytes
and osteoblasts, with Twist2-Cre or specifically from
chondrocytes withCol2-Cre results in similar phenotypes,
supporting the conclusion that MEF2C functions primarily
to regulate chondrocyte hypertrophy. We interpret the dif-
ferences between the Mef2c and Runx2 mutant pheno-
types to indicate a primary role of MEF2C in hypertrophy
of endochondral cartilage.
How doesMEF2 regulate chondrocyte hypertrophy and
bone development?Many of the actions of MEF2 on these
processes undoubtedly reflect the direct activation of
downstream target genes, such as the Col10a1 gene,
a specific marker for chondrocyte hypertrophy, which
serves as a direct transcriptional target of MEF2. It is note-
worthy that Runx2 expression was also dramatically di-
minished in the endochondral cartilage of Mef2c mutant
mice, suggesting that MEF2C is required, either directly
or indirectly, for Runx2 expression, and that some of the
defects of Mef2c mutant mice may be attributable to di-
minished expression of Runx2. MEF2C is also essential
for normal expression of VEGF within the endochondral
cartilage, which regulates angiogenesis in the late stages
of chondrocyte development. In addition, Ihh fails to be
upregulated in prehypertrophic chondrocytes of Mef2c
mutant mice. Ihh plays multiple roles in endochondral
bone development by enhancing chondrocyte prolifera-
tion (St-Jacques et al., 1999; Long et al., 2001) and stim-
ulating PTHrP synthesis, thereby regulating a negative
feedback loop to govern the timing of hypertrophy
(St-Jacques et al., 1999; Vortkamp et al., 1996). The failure
of Ihh to be upregulated in prehypertrophic chondro-
cytes of Mef2c mutant mice could contribute to the trun-
cations of endochondral bones in these animals. MEF2C,
therefore, influences numerous interwoven steps of
signaling and gene activation during bone development.
Control of Bone Development by the Balance
of MEF2C and HDAC4
Impairment of chondrocyte hypertrophy resulting from
deletion of Mef2c or expression of MEF2C-Engrailed in
endochondral cartilage is the opposite of the phenotype
resulting from genetic deletion of Hdac4 (Vega et al.,
2004), which results in premature ossification and fusionental Cell 12, 377–389, March 2007 ª2007 Elsevier Inc. 385
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Control of Bone Development by MEF2CFigure 6. Regulation of the Col10a1 Promoter by MEF2
(A) Comparison of potential MEF2-binding sites in the Col10a1 promoter to the MEF2-binding consensus. All of the selected sites match the core
TAWWWWTAof theMEF2-binding consensus.MEF2-binding sites conserved between themouseand humangenomes are indicatedwith anasterisk (*).386 Developmental Cell 12, 377–389, March 2007 ª2007 Elsevier Inc.
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Control of Bone Development by MEF2CFigure 7. A Model for Transcriptional
Regulation of Bone Development by
MEF2C and HDAC4
HDAC4 repression in chondrocytes is medi-
ated by MEF2 and Runx transcription factors.
MEF2 factors function to regulate chondrocyte
hypertrophy, while Runx factors are required
for both chondrocyte hypertrophy and osteo-
blast development.of the growth plates. Conversely, the premature and ec-
topic ossification of endochondral bones resulting from
expression of MEF2C-VP16 is similar to, but more se-
vere than, that of Hdac4 null mice. Altering the balance
between the opposing actions of MEF2C and HDAC4
can dictate the extent of chondrocyte hypertrophy and
ossification in predictable ways. Failure of endochondral
ossification resulting from heterozygosity of Mef2c, for
example, can be rescued in a dose-dependent manner
by removal of Hdac4 alleles, whereas the premature
and ectopic ossification in Hdac4 mutant mice can be
reversed by deletion of a Mef2c allele. The rescue of
the Hdac4 mutant phenotype with a heterozygous
Mef2c allele provides the strongest genetic evidence
to date for the opposing actions of MEF2 and class II
HDACs in vivo.
Misregulation of signaling pathways that influence
growth plate dynamics results in dwarfisms and bone de-
formations due to either accelerated maturation of the
growth plate cartilage, characteristic of achondroplasia,Developor delayed or absent chondrocyte maturation, character-
istic of many chondrodysplastic syndromes (Zelzer and
Olsen, 2003; Kronenberg, 2003). Our results demonstrate
that growth plate dynamics can be modified by the bal-
ance of MEF2C and its repressor, HDAC4. The realization
that bone formation is controlled by the partnership of
MEF2C and HDAC4 suggests possibilities for therapeuti-
cally manipulating endochondral bone growth by modu-
lating the signaling pathways that govern the association
of HDAC4 with MEF2C. Moreover, our results suggest
that HDAC inhibitors currently in clinical trials for cancer,
neurodegenerative diseases, and other disorders may
also promote bone formation.
Commonalities of Developmental Processes
Controlled by MEF2 and Class II HDACs
MEF2 transcription factors are well known regulators of
skeletal muscle differentiation and fiber type switching,
as well as cardiovascular development, heart growth,
and neuronal development (reviewed in McKinsey et al.,(B) COS7 cells were transfected with a luciferase reporter controlled by the wild-type Col10a1 upstream region or the same region in which the MEF2
sites were disrupted by point mutations and increasing amounts of MEF2C-myc or a constitutively nuclear HDAC4 mutant (HDAC S/A), as indicated.
Error bars indicate one standard deviation.
(C) Electromobility shift assays of MEF2 binding to sites in theCol10a1 promoter. Oligonucleotides containing MEF2 sites from theCol10a1 promoter
were labeled with 32P and were assayed for myc-MEF2C binding. MEF2C was supershifted with an anti-myc antibody (Anti-myc) or competed with
100 molar excess of the Srpk3MEF2-binding site (cold competitor) and compared to reticulocyte lysate that did not contain MEF2C () or binding of
a labeled probe containing the corresponding MEF2 site disrupted by point mutations (M). MEF2-binding sites conserved between the mouse and
human genomes are indicated with an asterisk (*).
(D) b-galactosidase staining of E18.5 mice transgenic for Col10-lacZ. Note the strong expression of the transgene in the growth plates. H&E sections
of the radius and sternum show specific expression of the transgene in hypertrophic chondrocytes.
(E) Mutation of the MEF2-binding sites in the Col10-lacZ transgene diminishes the expression of b-galactosidase in hypertrophic chondrocytes,
demonstrating the requirement of MEF2 factors in the activation of the Col10-lacZ transgene.
(F) Opposing influences of MEF2C and HDAC4 on mineralization of sternal and rib cartilage. Anterior views of the sternum and ribs of mice stained
for bone (red) and cartilage (blue) at (Fa–Ff) P1 and (Fg–Fl) P8. Genotypes are indicated at the top. The manubrium (m) and xiphoid process (x) are
identified in (Fg). Arrows mark sites of ossification that are altered by the balance of Mef2c and Hdac4.mental Cell 12, 377–389, March 2007 ª2007 Elsevier Inc. 387
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cesses by governing MEF2 transcriptional activity. The re-
sults of the present study indicate that these seemingly
unrelated processes of cell differentiation, tissue growth,
and remodeling share an underlying commonality with
the regulatory mechanisms that control bone develop-
ment. Specificity in each case is dictated by the associa-
tion of MEF2 and class II HDACs with other cell type-
specific and signal-responsive transcriptional regulators.
Given the importance of MEF2 for vascular development
(Lin et al., 1998) and bone formation, it will be of interest
to determine whether the developmental mechanism de-
scribed here is also operative in the settings of vascular
calcification, which is among the most common cardio-
vascular disorders.
EXPERIMENTAL PROCEDURES
Creation of a Conditional Mef2c Mutant Allele
Methods for creation of theMef2c allele and generation of mutant mice
are described in Supplemental Data.
Transgenic Mice
Chondrocyte-specific transgenes were constructed by subcloning
either an in-frame fusion of the MEF2C DNA-binding domain and the
Engrailed repressor or an in-frame fusion of MEF2C and the VP16 ac-
tivation domain, between a 3 kb fragment of the Col2a1 promoter and
its 3 kb chondrocyte-specific enhancer region (Zhou et al., 1998).
Linearized transgenic constructs were injected into the pronuclei of
fertilized oocytes. Embryos were harvested and analyzed for changes
in skeletal development. The severity of the skeletal phenotype in
these mice correlated with transgene copy number.
Tissue Culture and Transfection
COS7 cells were grown in DMEM with 10% FBS. Fugene 6 (Roche)
was used for transient transfection according to the manufacturer’s in-
structions. A reporter plasmid containing 4.5 kb of the Col10a1 locus
was generated by PCR and was cloned into pGL3-basic (Promega).
Expression constructs for MEF2C, HDAC4, and Runx2 have been pre-
viously described (McKinsey et al., 2000; Vega et al., 2004). Plasmids
were cotransfected with 10 ng of a CMV-b-galactosidase reporter
plasmid to control for transfection efficiency.
Electromobility Shift Assays
MEF2C was translated in vitro in a coupled transcription-translation T7
reticulocyte lysate system (Promega). In vitro binding analysis was per-
formed as previously described (Wang et al., 2001), by using oligonu-
cleotide fragments that contained a MEF2-binding site from the
Col10a1 promoter, which competed with a MEF2-binding site from
the Srpk3 promoter (Nakagawa et al., 2005). Oligonucleotide se-
quences are available upon request.
Tissue-Specific Deletion of Mef2c
To generate mice that lack MEF2C in specific tissues, mice heterozy-
gous for the null allele of Mef2c were mated to mice bearing the des-
ignated Cre transgene or knockin. The resulting mice were mated to
mice homozygous for the Mef2cloxP allele to produce conditional null
mice. Mesoderm deletion of Mef2c was performed by using the
Twist2-Cre knockin (Yu et al., 2003). Chondrocyte deletion was per-
formed by using Col2-Cre (Long et al., 2001). All animal experimental
procedures were reviewed and approved by the Institutional Animal
Care and Use Committees at the University of Texas Southwestern
Medical Center.388 Developmental Cell 12, 377–389, March 2007 ª2007 ElsevCartilage and Bone Staining
Euthanized mice were skinned, eviscerated, and fixed overnight in
100% ethanol. Adult animals were additionally incubated overnight
in acetone to clear fatty tissues. All specimens were then stained
with Alcian blue for 48 hr. Soft tissues were removed by incubation
in 2% KOH as needed, and specimens were stained with Alizarin red
for 30–90 min as needed. Tissues were cleared in 1% KOH, 20% glyc-
erol and were photographed in 50% ethanol, 50% glycerol. Staining
reagents were prepared as described previously (McLeod, 1980).
Histology and b-Galactosidase Staining
Tissues were fixed in 10% phosphate-buffered formalin at 4C. Sam-
ples were then embedded in paraffin, sectioned at 5 mm, and stained
with hematoxylin and eosin or with von Kossa’s method. Briefly, sec-
tions were deparaffinized and immersed in 5% silver nitrate solution
for 30minwhile being exposed to a 100W light bulb. Slides were rinsed
in distilled water and immersed in 5% sodium thiosulfate for 3 min.
Slides were rinsed again in distilled water and counterstained with
nuclear fast red for 5 min. Methods for b-galactosidase staining of
transgenic embryos are described in Supplemental Data.
In Situ Hybridization
Tissue samples were fixed overnight in DEPC-treated 4% paraformal-
dehyde. Riboprobes were labeled with 35S-UTP by using the MAXI-
script in vitro transcription kit (Ambion; Austin, Texas). In situ hybridiza-
tion of sectioned tissues was performed as previously described
(Vega et al., 2004).
Supplemental Data
Supplemental Data include the strategy for creation of the conditional
Mef2c mutant allele and analysis of markers of bone development in
mutant embryos and are available at http://www.developmentalcell.
com/cgi/content/full/12/3/377/DC1/.
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